STTK.US Shattuck Labs Inc

Healthcare Biotechnology USA Stocks
4.58 USD
Close of Nov 17, 2026
1.88 8.33
Market cap
USD 466M
P/E
-
P/B
2.45x
ROE
-38.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is STTK.US undervalued?

Graham number

The Graham number of Shattuck Labs Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Shattuck Labs Inc fundamental analysis

No fundamental analysis for Shattuck Labs Inc yet.

Shattuck Labs Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Shattuck Labs Inc

Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxici…

Full company profile